Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

333
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
333

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human Exposures to Micro- and Nanoplastics in Water and Data Needed to Understand Potential Health Effects-A-State of the Science Review.

Microplastics (Basel, Switzerland)·2026
Same author

Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.

MMWR. Morbidity and mortality weekly report·2026
Same author

Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.

British journal of haematology·2026
Same author

Characterizing pediatric xylazine exposures reported to United States poison centers, 2010-2024.

Clinical toxicology (Philadelphia, Pa.)·2026
Same author

Understanding the Potential Risks of Consuming Raw Morel Mushrooms: Challenges and Lessons Learned from a Recent Outbreak Linked to Raw Morel Mushrooms.

Food protection trends·2026
Same author

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN.

The New England journal of medicine·2025

Related Experiment Video

Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved

Peter Hillmen1, Regina Horneff2, Michael Yeh1

  • 1Apellis Pharmaceuticals, Inc., Waltham, MA 02451, USA.

International Journal of Molecular Sciences
|September 14, 2024
PubMed
Summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder caused by PIGA gene mutations. Treatments target complement pathways, with a focus on C3/C3b inhibitors like pegcetacoplan for PNH.

Keywords:
C3 inhibitorC5 inhibitorcomplementfactor B inhibitorfactor D inhibitorparoxysmal nocturnal hemoglobinuriapegcetacoplan

More Related Videos

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria
08:11

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria

Published on: May 16, 2025

82
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Experiment Videos

Last Updated: Jun 13, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria
08:11

Studying Copper Nanoparticle-Induced Programmed Cell Death in Bacteria

Published on: May 16, 2025

82
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Area of Science:

  • Hematology
  • Immunology
  • Genetics

Background:

  • Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening hematologic disorder.
  • Caused by somatic mutations in the PIGA gene, leading to deficient CD55/CD59 expression on blood cells.
  • Deficiency results in complement-mediated hemolysis, anemia, and thrombosis.

Purpose of the Study:

  • To review the mechanisms of action of complement inhibitors for PNH.
  • To focus on C3/C3b-targeted therapy, specifically pegcetacoplan.
  • To provide insights into PNH molecular underpinnings through treatment profiles.

Main Methods:

  • Narrative review of current PNH treatments.
  • Analysis of complement inhibition at C5, C3, and alternative pathway initiation levels.
  • Focus on approved PNH therapies including C5 inhibitors, C3/C3b inhibitors, and factor B/D inhibitors.

Main Results:

  • Six complement inhibitors are currently approved for PNH.
  • Treatments target distinct points in the complement activation pathway.
  • Varying treatment profiles offer insights into PNH disease control.

Conclusions:

  • Complement inhibitors offer diverse therapeutic strategies for PNH.
  • Pegcetacoplan represents a key C3/C3b-targeted therapy.
  • Understanding treatment mechanisms enhances PNH management and research.